Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on June 10, 2025, reporting a material event regarding its capital structure. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the status of the Series B Right Warrants.
Material Changes
- Warrant Expiration: The 5-day volume weighted average price (VWAP) of the company's common stock over the five trading days prior to June 10, 2025, fell below the minimum required price of $2.00 per share.
- Consequence: As a result, the Series B Right Warrants issued in connection with a previously announced Rights Offering expired worthless pursuant to their terms.
- Refunds: Any payments received for the exercise of these warrants that were not applied will be refunded to holders without interest or penalty.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The primary contingency addressed is the expiration of the warrants due to the stock price condition not being met.
Investor Verification Checklist
- Verify the 5-day VWAP of CTSO stock leading up to June 10, 2025, to confirm it was below $2.00.
- Confirm the specific terms of the Series B Right Warrants regarding the expiration trigger.
- Check for subsequent announcements regarding the refund process for warrant exercise payments.
- Review the original Rights Offering prospectus to understand the full scope of the expired instrument.